



36 **Abstract**

37 In this study, we present the results of the first large-scale multinational study (36,220 participants)  
38 that measures vaccine hesitancy among Arab-speaking subjects. Our analysis shows a significant  
39 rate of vaccine hesitancy among Arabs in and outside the Arab region (83% and 81%, respectively).  
40 The most cited reasons for hesitancy are concerns about side effects and distrust in healthcare  
41 policies, vaccine expedited production, published studies and vaccine producing companies. We  
42 also found that female participants, participants 30-59 year-old, those with no chronic diseases,  
43 those with lower-level of academic education, and those who do not know the type of vaccine  
44 authorized in their countries are more hesitant to receive COVID-19 vaccination. On the other  
45 hand, participants who regularly receive the influenza vaccine, health care workers, and those from  
46 countries with higher rates of COVID-19 infections showed more vaccination willingness.  
47 Interactive representation of our results is posted on our project website at  
48 <https://mainapp.shinyapps.io/CVHAA>.

49

## 50 **Introduction**

51 It has been recognized early on that the race to produce Covid-19 vaccines will not halt the  
52 pandemic unless there is a general acceptance by the public to take the vaccine<sup>1,2</sup>. Therefore, Covid-  
53 19 vaccination hesitancy has been studied heavily before and since the early stage of vaccine  
54 availability, with high variation in the willingness to be vaccinated among different communities<sup>3-</sup>  
55 <sup>5</sup>. Several large multinational studies on vaccine acceptance have been conducted in 19 countries  
56 (n=13,426)<sup>6</sup>, 15 countries (n=18,526)<sup>7</sup>, 15 countries (n= 13,500)<sup>8</sup>, 14 countries (n= 12,777)<sup>9</sup>, and 7  
57 countries (n = 7,662)<sup>1</sup>. Interestingly, none of which covered Arabic speaking nations. A smaller  
58 multinational study that surveyed 3,414 participants was conducted in Jordan and Kuwait, with  
59 minor participation from some other Arab countries<sup>10</sup>. This study showed that vaccine acceptance  
60 was low (29.4%) and was lower in females, individuals with lower academic education, and  
61 individuals with no chronic diseases.

62 Other studies have been conducted in Saudi Arabia (n =1000)<sup>11</sup> and (n=3,101)<sup>12</sup>, Egypt (n=559)<sup>13</sup>,  
63 Jordan (n =3100)<sup>14</sup>, and the UAE (n =1,109)<sup>15</sup>. With the Arab nations having significant variations  
64 socioeconomically, politically and in the measures taken to control the pandemic, the study of  
65 reactions to and acceptance of the vaccine becomes necessary. Also, the authorization of the use  
66 of Sinopharm vaccine by some Arab countries, despite the lack of sufficient safety and  
67 effectiveness evidence<sup>16</sup>, may have an impact on the public's trust in the vaccine and the health  
68 policies in these countries. Furthermore, attitudes towards the vaccines are affected by complex  
69 and dynamic interplaying factors, and considerable changes over time have been observed in  
70 acceptance and hesitancy rates<sup>6-9,17-19</sup>. For all of these reasons, the earlier local studies cannot be  
71 generalized to the Arab world and further larger studies will present a clearer picture of the region.  
72 Arab countries and territories (23 in total) span a large geographical area in North Africa and West  
73 Asia with a population of over 440 million<sup>20</sup>. The total reported number of COVID-19 cases in the  
74 region until the mid-February 2021 was more than 4.1 million with 70.7 thousand deaths<sup>21</sup>

75 (Supplementary Fig 1). Yet, the Arab region is understudied, despite the geographical spread, the  
76 number of residents, and the number of cases and deaths. So, a large-scale multinational study for  
77 this area is necessary.

78 Our study aims to fill the gaps by investigating vaccine acceptance using a large-scale survey  
79 targeting the relatively understudied Arab populations living in different countries around the  
80 world following vaccine availability and administration. Secondly, to unveil the barriers leading to  
81 vaccine hesitancy and their prevalence among the participants using an extensive updated list of  
82 barriers against vaccine acceptance. Thirdly, the study compares the answers of the respondents  
83 residing in and outside the Arab world to evaluate the effect of socioeconomic, cultural, health  
84 policies and political differences on their reported attitudes and barriers to acceptance.

85

## 86 **Methods**

87 The Survey of Arab COVID-19 Vaccine Acceptance (SACVA) is an open online survey that was  
88 conducted using the online platform [www.surveypal.com](http://www.surveypal.com) from 14-Jan 2021 to 29-Jan, 2021.  
89 The sample population was a convenience sample targeted through a digital campaign using social  
90 media platforms. Institutional Review Board (IRB) approval was obtained from the last author's  
91 institution. Unique IP addresses are allowed to participate once on the survey platform to prevent  
92 multiple entries. Consent to participate was obtained at the first entry of the survey portal for each  
93 participant. The platform allows participants to move through screens only when answers were  
94 obtained, which prevents missing entries. The survey consisted of 17 questions, including the  
95 consent to participate. All questions were written and validated in the Arabic language- an English  
96 translation of the questions can be found on Supplementary Document 1. Questions two to nine  
97 captured demographics and current health status; question 10 was about the annual influenza  
98 vaccine; question 11 was about available vaccine(s) in each country (if known) and answers to  
99 subsequent questions were directed based on the type of available vaccine(s). Questions 12 and 13  
100 queried whether the participant received the COVID-19 vaccination and if they had any side  
101 effects. Those who had already taken the vaccine were not allowed to answer question 14 which  
102 queried participant's acceptance/hesitance towards COVID-19 vaccine; these participants were not  
103 included in the analysis reported in this paper. Questions 15 and 16 surveyed participants' attitudes  
104 towards the need for COVID-19 vaccination and associated health policies. Question 17 was a  
105 detailed question that evaluated 29 barriers which potentially influenced the decision to receive the  
106 vaccine in addition to "I do not have any reservations about taking the vaccine" option. We also  
107 allowed participants who answered "Yes", meaning they are willing to be vaccinated, to choose  
108 from the 29 barriers.

109 Questions were discussed thoroughly among authors and other colleagues. Face validity was tested  
110 by the third author, who has expertise in the domain. A pilot survey was then posted online and

111 100 individuals participated following direct contacts by authors. Analyzing responses and  
112 comments of this pilot survey helped in refining the final survey and confirming its validity and  
113 reliability.

114 The survey data was analyzed using R software- v.4.0.2. Descriptive statistics and analytical graphs  
115 were used as needed. Participants were also subcategorized based on country of residence. Arab  
116 countries with less than 100 participants (Somalia, Djibouti and Comoros) were grouped together  
117 in one category and labeled “Other Arab countries”. The non-Arab countries where the Arabic  
118 speaking respondents were residing were classified into groups: European countries (n=30), North  
119 American countries (n=3), Turkey and the rest of non-Arab countries as others (n=88). The  
120 answers to the 14<sup>th</sup> question, “Do you intend to take the vaccine?”, were used as a dependent  
121 variable and were analyzed using binary logistic regression. Two of the answer choices (“Yes”,  
122 “Depends on the type of vaccine”) were used to define vaccine acceptance while the other three  
123 (“No”, “Not sure”, “I will wait and see its effects on others”) were labeled as “Vaccine Hesitancy”.  
124 Responses to the question of the barriers to acceptance (Question 17) were compared for gender,  
125 academic education and country of residence using Chi-Square. Our acquisition and analysis of the  
126 results followed the guidelines of the CHERRIES checklist<sup>22</sup>.

127 As for COVID-19 cases and death statistics, we used the COVID19 package- v2.3.2- which collects  
128 data from different sources to provide up-to-date COVID-19 statistics<sup>23</sup>. The total number of  
129 confirmed cases and deaths were correlated with vaccine acceptance in different Arab countries  
130 using the Spearman correlation. The results of the survey can be found on the project’s website at  
131 <https://mainapp.shinyapps.io/CVHAA>.

132

133

134 **Results**

135 *Demographics*

136 Our online survey raw data were downloaded on January 29<sup>th</sup>, 2021; there were 38,485 participants  
137 who started filling the survey of whom 36,958 consented and proceeded with the survey. A total  
138 of 738 participants reported receiving COVID-19 vaccination before filling the survey and were  
139 excluded from further analysis in this report bringing the total respondents who qualify for analysis  
140 to 36,220. The participants cover all the 23 Arab countries and territories (n=30,200, 83.4%) and  
141 Arabs who live in 122 other countries (n= 6,020, 16.6%). Participants from countries out of the  
142 Arab region were clustered into four groups: Europe (N=3130, 52%), North America (n=748,  
143 12.4%), Turkey (n=1630, 27.1%) and others (n=512, 8.5%).

144 The mean age was 32.6 years ( $\pm 10.8$ ). There were more males (n=22,040, 61.1%) than females  
145 (n=14,180, 38.9%)- Supplementary Fig 2. Chronic diseases were reported by 5,839 participants  
146 (16.1%). Previous COVID-19 infection- suspected or confirmed- was reported by 6,637 (18.3%)  
147 participants; 11,458 (31.6%) other participants were not sure if they had contracted the virus.  
148 Among the 4,494 participants who reported testing for COVID-19, there were 2,792 participants  
149 with positive test results (62.1% positivity). Only 908 (2.5%) participants reported annual influenza  
150 vaccine while 28,040 (77.4%) reported never receiving it. More than half of the participants had a  
151 bachelor's degree or higher (22,236, 61.4%). Being a health care worker was reported by 5,708  
152 participants (15.8%). When asked about the type of vaccine available in their countries, 15,057  
153 (41.6%) did not know the type, while vaccines made in China and the United States were reported  
154 by 12,374 and 12,254 participants, respectively. Detailed participant characteristics are shown in  
155 Table 1.

156

157 Table 1. Characteristics of Participants with Distribution of COVID-19 Vaccine Willingness

Variables	Levels	No		Not Sure		Will wait for others		Depending on type		Yes	
		N	%	N	%	N	%	N	%	N	%
<b>Age</b>	Below 29	5871	37.2%	3607	22.9%	3591	22.8%	899	5.7%	1803	11.4%
	30-39	4939	42.7%	2484	21.5%	2225	19.2%	463	4.0%	1454	12.6%
	40-49	2563	43.3%	1213	20.5%	1156	19.5%	160	2.7%	827	14.0%
	50-59	1009	43.9%	429	18.6%	455	19.8%	72	3.1%	336	14.6%
	Over 60	267	40.2%	123	18.5%	125	18.8%	21	3.2%	128	19.3%
<b>Chronic Diseases</b>	No	12390	40.8%	6614	21.8%	6292	20.7%	1368	4.5%	3717	12.2%
	Yes	2259	38.7%	1242	21.3%	1260	21.6%	247	4.2%	831	14.2%
<b>Country</b>	Arab countries	12534	41.5%	6414	21.2%	6220	20.6%	1464	4.8%	3568	11.8%
	Other countries	2115	35.1%	1442	24.0%	1332	22.1%	151	2.5%	980	16.3%
<b>Academic Education</b>	Higher education	9128	41.1%	4752	21.4%	4277	19.2%	1027	4.6%	3052	13.7%
	Lower education	5521	39.5%	3104	22.2%	3275	23.4%	588	4.2%	1496	10.7%
<b>Had Covid</b>	No	7147	39.4%	3885	21.4%	3703	20.4%	780	4.3%	2610	14.4%
	Not sure	4445	38.8%	2628	22.9%	2642	23.1%	548	4.8%	1195	10.4%
	Yes	3057	46.1%	1343	20.2%	1207	18.2%	287	4.3%	743	11.2%
<b>Job</b>	HCW	1886	33.0%	1266	22.2%	1034	18.1%	432	7.6%	1090	19.1%
	Not HCW	12763	41.8%	6590	21.6%	6518	21.4%	1183	3.9%	3458	11.3%
<b>Gender</b>	Male	8152	37.0%	4625	21.0%	4776	21.7%	1152	5.2%	3335	15.1%
	Female	6497	45.8%	3231	22.8%	2776	19.6%	463	3.3%	1213	8.6%
<b>Influenza Vaccine</b>	Yearly	166	18.3%	159	17.5%	170	18.7%	62	6.8%	351	38.7%
	Some years	687	23.6%	627	21.5%	678	23.3%	180	6.2%	739	25.4%
	Rarely	1324	30.4%	1019	23.4%	1117	25.6%	228	5.2%	673	15.4%
	Never	12472	44.5%	6051	21.6%	5587	19.9%	1145	4.1%	2785	9.9%
<b>Vaccine Type Unknown</b>	No	7937	37.5%	4356	20.6%	4364	20.6%	1141	5.4%	3365	15.9%
	Yes	6712	44.6%	3500	23.2%	3188	21.2%	474	3.1%	1183	7.9%

158 *COVID-19 Vaccination Hesitancy and related factors*


159 When asked about their willingness to receive COVID-19 vaccine if the option is available to them;  
160 4,548 (12.6%) of the respondents answered “Yes”; 1,615 (4.5%), answered “Depends on the type  
161 of vaccine”; 7,552 (20.9%) answered “I will wait and see its effects on others”; 7,856 (21.7%)  
162 answered “I am not sure”; and 14,649 (40.4%) chose “No”. The first two choices were considered  
163 acceptance to receive a vaccine while the last three were labelled as vaccine hesitancy (Fig 1).

164 Variations in responses were analyzed using different factors as covariates (Fig 2).

165 Respondents from the Arab Gulf countries (Qatar, Oman, Kuwait, Bahrain, Saudi Arabia and UAE)  
166 plus Libya and Sudan showed the highest willingness for vaccination while those who showed the  
167 least willingness are participants from the west region (Algeria, Tunisia, Mauritania and Morocco)-  
168 Fig 1. Arabic speaking participants living in North America were more willing to receive  
169 vaccination than those in the other three clusters (Fig 1, Table 2).


170 Several factors (shown in Fig 3, Table 3) were tested in a binomial logistic regression model to  
171 examine their correlation with vaccine hesitancy. Univariate and multivariate analyses showed  
172 that almost all tested factors were significant predictors for vaccine hesitancy, reflecting the large  
173 sample size tested. Odds ratio showed the stronger effect of the following factors on participants’  
174 hesitance: Never (OR, 4.04) or rarely (OR, 2.69) receiving the influenza vaccine, not knowing the  
175 vaccine type available (OR, 1.93), female gender (OR, 1.91), and outside of the healthcare system  
176 (OR, 1.84). Vaccine acceptance in each Arab country was correlated with the number of confirmed  
177 COVID19 cases and deaths using Spearman correlation. It was found out that the number of cases  
178 ( $p=0.0047$ ) but not deaths ( $p=0.3$ ) correlated significantly with vaccine acceptance- supplementary  
179 Fig 3.

180




181

182 **Figure 1. COVID-19 Vaccination attitudes among 36,220 participants.** A) Vaccine acceptance in the per-country  
 183 in the Arab region, B) Vaccination attitudes reported by participants from the Arab countries and territories, C)  
 184 Vaccination attitudes reported by participants from countries other than Arab countries and territories, D) Vaccination  
 185 attitudes reported by participants per Arab country/territory, and E) Vaccination attitudes reported by participants from  
 186 countries other than Arab countries and territories clustered by residency region.  
 187



188  
189  
190  
191  
192  
193

**Figure 2. Differences in COVID-19 Vaccination attitudes among participants** according to (A) country of residence, (B) age, (C) level of academic education, (D) being a healthcare worker, (E) having a chronic illness, (F) knowing the vaccine type available in participant's country, (G) having a previous COVID-19 infection, (H) age and (I) receiving annual influenza vaccine.



194  
 195 **Figure 3.** Multivariate analysis results of COVID-19 vaccine acceptance/hesitancy stratified according to different  
 196 factors; odds ratio (OR) and 95% confidence intervals (CI) are shown; the size of the box represents the number of  
 197 participants in each level.  
 198

199 Table 2. List of Surveyed Countries and the Frequency (%) of Participants COVID-19 Vaccination  
 200 Choices  
 201

Country	No		Not Sure		Will wait for others		Depending on type		Yes	
	N	%	N	%	N	%	N	%	N	%
<b>Algeria</b>	1675	61.9%	509	18.8%	343	12.7%	81	3.0%	98	3.6%
<b>Bahrain</b>	40	34.8%	22	19.1%	28	24.3%	6	5.2%	19	16.5%
<b>Egypt</b>	1949	36.5%	1166	21.8%	1315	24.6%	480	9.0%	429	8.0%
<b>Europe</b>	1139	36.4%	749	23.9%	677	21.6%	61	1.9%	504	16.1%
<b>Iraq</b>	204	34.8%	113	19.3%	163	27.8%	28	4.8%	78	13.3%
<b>Jordan</b>	3032	43.2%	1283	18.3%	1407	20.0%	369	5.3%	929	13.2%
<b>Kuwait</b>	168	31.8%	115	21.7%	122	23.1%	7	1.3%	117	22.1%
<b>Lebanon</b>	205	41.7%	104	21.1%	110	22.4%	14	2.8%	59	12.0%
<b>Libya</b>	65	28.4%	64	27.9%	51	22.3%	11	4.8%	38	16.6%
<b>Mauritania</b>	39	39.4%	32	32.3%	17	17.2%	3	3.0%	8	8.1%
<b>Morocco</b>	1750	46.4%	961	25.5%	631	16.7%	135	3.6%	298	7.9%
<b>North America</b>	259	34.6%	170	22.7%	142	19.0%	10	1.3%	167	22.3%
<b>Oman</b>	66	35.3%	40	21.4%	36	19.3%	7	3.7%	38	20.3%
<b>Other Arabs</b>	18	34.0%	15	28.3%	14	26.4%	3	5.7%	3	5.7%
<b>Others</b>	183	35.7%	137	26.8%	103	20.1%	15	2.9%	74	14.5%
<b>Palestine</b>	568	35.0%	392	24.1%	336	20.7%	77	4.7%	251	15.5%
<b>Qatar</b>	114	25.7%	113	25.5%	89	20.1%	7	1.6%	120	27.1%
<b>Saudi Arabia</b>	1240	34.6%	761	21.2%	822	22.9%	74	2.1%	691	19.3%
<b>Sudan</b>	136	43.5%	60	19.2%	50	16.0%	19	6.1%	48	15.3%
<b>Syria</b>	504	40.9%	266	21.6%	279	22.6%	51	4.1%	132	10.7%
<b>Tunisia</b>	358	53.8%	120	18.0%	125	18.8%	19	2.9%	43	6.5%
<b>Turkey</b>	534	32.8%	386	23.7%	410	25.2%	65	4.0%	235	14.4%
<b>UAE</b>	280	28.6%	245	25.0%	246	25.1%	60	6.1%	148	15.1%
<b>Yemen</b>	123	54.4%	33	14.6%	36	15.9%	13	5.8%	21	9.3%

202 Table 3. Predictors of Vaccine Hesitancy Tested by Univariate and Multivariate Binary Logistic  
 203 Regression  
 204

Variable	Levels	Acceptance	Hesitance	Univariate	Multivariate
		N (%)	N (%)	OR (95% CI)	OR (95% CI)
<b>Age</b>	Below 29	2702 (17.1)	13069 (82.9)	-	-
	30-39	1917 (16.6)	9648 (83.4)	1.04 (0.98-1.11)	1.18 (1.10-1.26)
	40-49	987 (16.7)	4932 (83.3)	1.03 (0.95-1.12)	1.14 (1.05-1.24)
	50-59	408 (17.7)	1893 (82.3)	0.96 (0.86-1.08)	1.03 (0.91-1.17)
	Over 60	149 (22.4)	515 (77.6)	0.71 (0.59-0.86)	0.89 (0.73-1.09)
<b>Chronic Diseases</b>	No	5085 (16.7)	25296 (83.3)	-	-
	Yes	1078 (18.5)	4761 (81.5)	0.89 (0.83-0.96)	0.91 (0.84-0.99)
<b>Country</b>	Arab countries	5032 (16.7)	25168 (83.3)	-	-
	Other countries	1131 (18.8)	4889 (81.2)	0.86 (0.80-0.93)	0.90 (0.84-0.98)
<b>Academic Education</b>	Higher education	4079 (18.3)	18157 (81.7)	-	-
	Lower education	2084 (14.9)	11900 (85.1)	1.28 (1.21-1.36)	1.18 (1.11-1.26)
<b>Had Covid</b>	No	3390 (18.7)	14735 (81.3)	-	-
	Not sure	1743 (15.2)	9715 (84.8)	1.28 (1.20-1.37)	1.30 (1.22-1.39)
	Yes	1030 (15.5)	5607 (84.5)	1.25 (1.16-1.35)	1.32 (1.22-1.43)
<b>Job</b>	HCW	1522 (26.7)	4186 (73.3)	-	-
	Not HCW	4641 (15.2)	25871 (84.8)	2.03 (1.90-2.17)	1.82 (1.70-1.96)
<b>Gender</b>	Male	4487 (20.4)	17553 (79.6)	-	-
	Female	1676 (11.8)	12504 (88.2)	1.91 (1.80-2.03)	1.90 (1.79-2.03)
<b>Vaccine Type Unknown</b>	No	4506 (21.3)	16657 (78.7)	-	-
	Yes	1657 (11.0)	13400 (89.0)	2.19 (2.06-2.33)	1.93 (1.81-2.06)
<b>Annual influenza vaccine</b>	Yearly	413 (45.5)	495 (54.5)	-	-
	Some years	919 (31.6)	1992 (68.4)	1.81 (1.55-2.11)	1.57 (1.34-1.83)
	Rarely	901 (20.7)	3460 (79.3)	3.20 (2.76-3.72)	2.70 (2.31-3.15)
	Never	3930 (14.0)	24110 (86.0)	5.12 (4.47-5.86)	4.08 (3.54-4.70)

206 *Barriers to acceptance*

207 There were 3,905 participants who chose acceptance but yet had one or more barrier(s) selected.  
208 Of the 29 barriers, the most common responses were “I am afraid side effects of the vaccine will  
209 develop, other than what has been disclosed”- 22,235 (61.4%), “Not enough time has passed to  
210 verify the vaccine’s safety”- 20,172 (55.7%), “The vaccine production has been rushed, making  
211 me doubt the credibility of the producing company”- 16,698 (46.1%), "I do not trust the healthcare  
212 policies applied in my country"- 14,151 (39.1%), and “I do not trust the published studies, nor the  
213 company producing the vaccine” in 11,968 responses (33%) (Fig 4).

214

215 *Comparison of participants inside and outside the Arab World*


216 Participants in the Arab World were slightly more likely to have vaccine hesitancy when compared  
217 to those living outside (83.3% vs. 81.2%)- Fig 1. Those living in North America were the least  
218 hesitant (76.3%) while those living in Turkey had the highest hesitancy (83.6%). Additionally,  
219 participants living in Arab countries were more likely to report “I do not trust the healthcare policies  
220 applied in my country”, “There are no published studies on the vaccine”, “I do not trust the  
221 published studies, nor the company producing the vaccine”, “No need for the vaccine as rates of  
222 viral infection are decreasing”, and “No need for the vaccine as most people in my country have  
223 already been infected” (chi-square test,  $p < 0.0001$ , with difference  $> 5\%$  for all) (supplementary  
224 table 1, supplementary Fig 4).

225

226 *Attitudes towards vaccination policies and need*


227 When asked about their opinions regarding suggested vaccination policies, participants’ responses  
228 were: To let people choose if they want to take it or not (59.5%), to mandate it on populations in  
229 which the vaccine was proven to be effective and safe as per clinical studies (13.6%), not sure  
230 (10.9%), should not be given to anybody (6.1%), and To give work and transportation privileges

231 to whomever takes the vaccine (3.9%). When asked who needs the vaccine, responses were:  
232 whomever- the vaccine was proven to be effective and safe as per clinical studies (35.4%), specific  
233 categories of people need it, but they're not the majority (30.5%), I don't know (24.9%), and No  
234 one needs it (9.2%) (Fig 5).  
235



236  
237  
238

**Figure 4. Barplot showing percentages of participants (N=36,220) who selected the shown barriers.**



239  
240 **Figure 5. Participants' attitudes towards COVID-19 vaccination in regards to (A) national health policies and (B)**  
241 **selecting individuals who should be vaccinated.**  
242

## 243 **Discussion**

244 This study presents the largest online survey on vaccine hesitancy that covered a heterogeneous  
245 population of Arabic people living all over the globe. In addition, it bridged the gap in knowledge  
246 on vaccine hesitancy in the Arab region. It shows low rates of vaccine acceptance in the face of the  
247 ongoing pandemic. Only one in eight respondents (12.5%) reported their willingness to take the  
248 vaccine. One in 22 (4.4%) based their decision on whether to take the vaccine or not on the type of  
249 the vaccine, acknowledging that the vaccine type they prefer may not be available in the near future  
250 and even when available, they may not be given the choice of selecting that vaccine type. These  
251 results are of unique significance because the study has been conducted after the vaccine has  
252 become available and administered to millions of people worldwide, and while about 70 different  
253 vaccine candidates are currently under development.

254 The study also showed a clear correlation between acceptance and gender, academic background,  
255 attitudes toward the flu shot, having been previously suspected of- or confirmed with- COVID-19  
256 infection and knowledge of the vaccine type. Females were more hesitant to take the vaccine, while  
257 the previous studies were inconclusive on the correlation of hesitance with gender, where women  
258 were found to have higher<sup>24-26</sup>, equal<sup>13</sup>, or lower<sup>6,27</sup> hesitancy compared with men. Our results  
259 show lower acceptance in participants with current or previous suspected or confirmed Covid-19  
260 infection (data) when compared with Lazarus et. al. (n=13,426) who found no significant  
261 correlation<sup>6</sup>. On the other hand, our results are consistent with the literature in terms of lower  
262 acceptance in people who do not get influenza vaccination<sup>5</sup> and who have lower academic  
263 education<sup>5,6</sup>.

264 Respondents who did not know the vaccine type available to them showed increased hesitancy.  
265 This may be attributed to the fact that some Arab countries were first to approve the Sinopharm  
266 vaccine despite lack of affirmative data<sup>16</sup>. The impact of vaccine efficacy on attitudes towards  
267 vaccination has been echoed in the study of Harapan et. al. (n=1,359)<sup>28</sup>, conducted before vaccine

268 availability, where 93.3% of respondents chose to be vaccinated with a 95% effective vaccine, but  
269 this acceptance rate decreased to 67.0% in the case of a vaccine with 50% effectiveness. The  
270 results showed a level of mistrust in healthcare policies in Arab countries (44%) which can also be  
271 attributed to the selection of certain vaccines, as well as the inability to choose which vaccine to  
272 take. all of these factors may contribute to high hesitance when the vaccine type is unknown to the  
273 participant.

274 Consistent with previous studies<sup>28,29</sup>, health care workers were more accepting of the vaccine,  
275 although with still low proportions of about one in four (18% yes and 7.1% depending on the type).  
276 One study on Congolese health care workers (n=613) conducted in March-April, 2020 reported a  
277 similar notably low rate of acceptance (only 27.7%)<sup>30</sup>. In addition, consistent with the results of  
278 the multinational study by Lazarus et. el. (n=13,426)<sup>6</sup>, participants from countries with higher per  
279 million Covid-19 cases were more likely to welcome the vaccine. Participants between the ages of  
280 30 and 59 were less willing to receive vaccination compared with older participants, an expected  
281 result given the fact that COVID-19 severity is associated with older age. However, younger  
282 participants (<29 years old) showed more willingness to be vaccinated.

283 Among the 29 different reasons for vaccine rejection/hesitancy, the top two reasons selected by the  
284 respondents reflected concerns about safety while the next three most prevalent reasons were issues  
285 of distrust. This is consistent with the literature which showed high levels of distrust and concern  
286 about safety<sup>5</sup>.

287 The three forms of distrust (in healthcare policies, in vaccine expedited production and in published  
288 studies) were notably higher among respondents residing in the Arab countries than those living  
289 outside the Arab world. The same applies to the belief that the vaccine has not been tested on a  
290 large enough number of people, just tens or hundreds, which reflects less awareness of the vaccine  
291 development process in the Arab countries and highlights the need to educate the general public  
292 on the subject. Similarly, more residents of the Arab world believe that the vaccine is not necessary

293 anymore because most people in the participant’s country “have already been infected” or because  
294 the infection rate is decreasing. The infection rate is in fact decreasing (supplementary Fig 1, panel  
295 A) but the public may need to be made aware that future outbreaks are still a possibility.  
296 With the high rate of distrust, any form of coercion to take the vaccine may have negative impacts.  
297 Lazarus’s et. al. large-scale study indicated that promoting voluntary acceptance is a better route  
298 and that coercion should be avoided<sup>6</sup>. Similarly, a systematic review indicated that “mandates could  
299 increase resistance”<sup>5</sup>. In our study, the majority of participants (59.5%) believed that vaccination  
300 should be left to individual choices and only a minority believed it should be mandated for certain  
301 categories of people (6.1%) or on populations in which the vaccine was proven to be effective and  
302 safe as per clinical studies (13.6%).

303 Approximately one-fifth of our respondents chose “The vaccine might lose its efficacy against the  
304 new viral strains” as a reason for hesitation. The survey was published shortly after reports of the  
305 new viral strains in the UK and South Africa have been made public, and with the recent reports  
306 of decreased efficacy of some vaccines<sup>31,32</sup>, this concern of efficacy is expected to increase among  
307 the public.

308 Several factors appear to contribute to the low level of vaccine acceptance in the current study  
309 compared with the previous works. First of all, the response to the question of willingness is broken  
310 down from Yes/No or Likert scale (in previous works) to a spectrum of choices which could more  
311 accurately detect the hesitant respondents who could have otherwise chosen (Yes) or  
312 (Agree/Strongly agree). In a large-scale survey conducted in October, 2020 that included 18,526  
313 adults across 15 countries<sup>7</sup>, 73% strongly agreed or agreed that “if a vaccine for COVID-19 were  
314 available, I would get it”. However, of those, only 22% agreed that they would become vaccinated  
315 ‘immediately after the vaccine is available’, while some others chose that they would wait for a  
316 year and even longer. The same study found out that there is less certainty about getting vaccinated  
317 among those who will wait. Thus, the affirmative nature of the Yes/No and 5-point Likert scales

318 do not seem to reflect the true nature of hesitancy and whether or not it changes its nature over  
319 time.

320 In 2015, the World Health Organization (WHO) Strategic Advisory Group of Experts on  
321 Immunization defined vaccine hesitancy as a ‘delay in acceptance or refusal of vaccination despite  
322 the availability of vaccination services’<sup>33</sup>. We, therefore, question considering those who intend to  
323 take the vaccine after a prolonged time of availability as “Accepting” since this may interfere with  
324 the targeted achievement of collective immunity.

325 In the present study, 20.8% of the participants chose (I will wait and see its effects on others)-  
326 many of whom could have possibly chosen (Yes) or (Agree) had the waiting choice been  
327 eliminated. A systematic review noted that “When answer options included different timings for  
328 vaccination, more people chose to wait than get it as soon as possible” and that the two answer  
329 choices (Yes/No) received relatively high affirmatives<sup>5</sup>. Only three out of about 70 studies and  
330 polls in this review included the choice of “wait a while until others have taken it” for the question  
331 of vaccine acceptance. In these three polls, conducted before vaccine availability, the percentage  
332 of those who chose that they would take the vaccine as soon as they can (or as soon as possible)  
333 was low (21%-28%). This indicates that vaccine acceptance may be overestimated in many studies  
334 and highlights the need to redefine vaccine acceptance in a uniform way among different studies.

335 Another factor that may explain the lower rate of acceptance observed in the study is the nature of  
336 our survey population. Social and political differences were found to have a prominent effect on  
337 Covid-19 vaccine acceptance, especially that many people assumed political interference in the  
338 vaccine and in the pandemic itself<sup>5</sup>. Vaccine acceptance was lower in Arab countries in previous  
339 studies: Jordan (37.4%)<sup>14</sup>, Saudi (64.72%)<sup>11</sup>, (44.7%)<sup>12</sup>, and in a small multinational survey that  
340 included several countries, mainly Jordan and Kuwait (29.4%)<sup>10</sup>.

341 The chronological analysis of vaccine acceptance and time- in local and multinational studies- does  
342 not show a linear relationship- if anything, the public’s acceptance can be best described as

343 fluctuating. Several surveys conducted in the last third of 2020 have shown a decrease in  
344 vaccination acceptance compared with previous surveys<sup>5,7,17,26</sup>. For example, the intent to vaccinate  
345 has declined in ten out of the 15 countries from August to October, 2020<sup>7</sup>. A systematic review of  
346 publications until 20 October, 2020 showed declining vaccine acceptance (from >70% in March to  
347 <50% in October) with demographic, socioeconomic, and partisan divides observed<sup>5</sup>. However, a  
348 more recent multinational survey conducted from November, 2020 to mid-January, 2021 in 15  
349 countries<sup>18</sup> and a study conducted from Jan 28th to 31st, 2020 in 14 countries<sup>9</sup> have both shown an  
350 increase in vaccine acceptance.

351 As for Arab countries, the more recent studies<sup>10,14,34</sup> show lower acceptance rates than the earlier  
352 ones. For example, A study conducted in Egypt (n=559) during March, 2020 found out that about  
353 73.0% were looking forward to getting the vaccine when available<sup>11-13</sup>. However, the more recent  
354 study on HCW in Egypt (n=496) during December, 2020 concluded that only 13.5% totally agree  
355 to receiving the vaccine, and 32.4% somewhat agree<sup>34</sup>. In our survey that is more recent than the  
356 mentioned studies, 17.0% and 24.0% of participants in Egypt (general [n= 5,339] and HCW [n=  
357 1,250], respectively) were willing to take the vaccine.

358 A Saudi Arabia study published in May, 2020 observed that 64.7% of participants (n=1000)  
359 showed interest to accept the COVID-19 vaccine if it is available<sup>11</sup>, and another study conducted  
360 during May (n=3,101) showed a 44.7% acceptance rate<sup>12</sup>. However, in a more recent study in Saudi  
361 Arabia too, published in December 2020, 31.8% of participants (n=154) showed acceptance<sup>10</sup>. In  
362 our survey that is more recent than the mentioned studies, 19.8% of participants from Saudi Arabia  
363 (n=3,588) showed acceptance.

364 This study comes with few limitations. Similar to several previous surveys<sup>5</sup>, participants were  
365 recruited through social media. Being an online survey, our study may have under-represented  
366 certain groups of individuals, including members of older age groups and those who are not active  
367 on social media. We cannot rule out selection bias that might have affected our results. Other

368 high-risk groups such as people with chronic diseases are well-represented (n=5,839) or even over-  
369 represented (HCW, n=5,708). Our sample size was not pre-planned but was rather arbitrary  
370 reflecting a convenience sample. We believe that the large number of participants and the  
371 consistency of results in different countries that were geographically close and similar  
372 socioeconomically confirm the reliability of our survey.

373

374 **Conclusion**

375 Our results show high COVID-19 vaccine hesitancy among Arab respondents residing inside and  
376 outside the Arab world after millions of people around the world have received the vaccine. The  
377 main reasons for hesitancy are concerns about safety and distrust in healthcare policies, vaccine  
378 expedited production and published studies, with the distrust being notably higher among  
379 respondents residing in the Arab countries. Given that the vaccine is being purchased from state  
380 expenditure, the high vaccine hesitancy could further compromise the economies of Arab countries  
381 in addition to the pandemic health hazard. At the same time, mandating the vaccine is not a  
382 desirable choice and could further increase the distrust. With the highly dynamic nature of the  
383 pandemic and vaccine production process and the interplay of ever-changing factors that affect  
384 vaccine acceptance, our study needs to be replicated at a later time to measure the change in public  
385 acceptance. The high proportion of people willing to wait until others have received the vaccine  
386 and the unavailability of the preferred vaccine for others shows a need to create a uniform definition  
387 for vaccine acceptance in the surveys to avoid misestimation.

388

389 **Supplementary Figures**

390 **Supplementary Figure 1.** The burden of COVID-19 outbreak on Arab countries with panels  
391 representing (A) the daily cases per million in different countries, (B) cumulative cases per million  
392 in each country, (C) total daily cases and deaths in all Arab countries, (D) cumulative number of  
393 confirmed cases and deaths in all Arab countries, and (E) a map showing the differences in total  
394 cumulative confirmed cases per million capita.

395 **Supplementary Figure 2.** A bar plot and a pie chart showing distribution of participants according  
396 to country of residence and gender

397 **Supplementary Figure 3.** Scatter plots showing correlation between vaccine acceptance in 36,220  
398 survey participants and (A) the total number of confirmed COVID-19 cases per million and (B) the  
399 total COVID-19 related deaths per million in Arab countries.

400 **Supplementary Figure 4.** Barriers to COVID-19 vaccine acceptance chosen by survey  
401 participants with percentage of selection for each barrier (out of a total of 36,220 participants)  
402 stratified according to (A) gender and (B) residence in or out of the Arab countries.

403

404


## 405 References

- 406 1. Neumann-Böhme, S. *et al.* Once we have it, will we use it? A European survey on  
407 willingness to be vaccinated against COVID-19. *European Journal of Health Economics*  
408 vol. 21 977–982 (2020).
- 409 2. Burgess, R. A. *et al.* The COVID-19 vaccines rush: participatory community engagement  
410 matters more than ever. *The Lancet* vol. 397 8–10 (2021).
- 411 3. Sallam, M. COVID-19 vaccine hesitancy worldwide: a systematic review of vaccine  
412 acceptance rates Author. *medRxiv* 2020.12.28.20248950 (2021)  
413 doi:10.1101/2020.12.28.20248950.
- 414 4. Feleszko, W., Lewulis, P., Czarnecki, A. & Waszkiewicz, P. Flattening the Curve of  
415 COVID-19 Vaccine Rejection—An International Overview. *Vaccines* **9**, 44 (2021).
- 416 5. Lin, C., Tu, P. & Beitsch, L. M. Confidence and Receptivity for COVID-19 Vaccines: A  
417 Rapid Systematic Review. *Vaccines* **9**, 16 (2020).
- 418 6. Lazarus, J. V. *et al.* A global survey of potential acceptance of a COVID-19 vaccine. *Nat.*  
419 *Med.* **27**, 225–228 (2020).
- 420 7. COVID-19 vaccination intent is decreasing globally | Ipsos.  
421 <https://www.ipsos.com/en/global-attitudes-covid-19-vaccine-october-2020>.
- 422 8. Mega, E. R. Trust in COVID vaccines is growing. *Nature* (2021) doi:10.1038/d41586-021-  
423 00368-6.
- 424 9. Global attitudes : COVID-19 vaccines | Ipsos. [https://www.ipsos.com/en-us/global-  
425 attitudes-covid-19-vaccine-january-2021](https://www.ipsos.com/en-us/global-attitudes-covid-19-vaccine-january-2021).
- 426 10. Sallam, M. *et al.* High Rates of COVID-19 Vaccine Hesitancy and Its Association with  
427 Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries. *Vaccines*  
428 **9**, 42 (2021).
- 429 11. Padhi, B. K. & AlMohaithef, M. A. Determinants of COVID-19 vaccine acceptance in  
430 Saudi Arabia: A web-based national survey. *medRxiv* 2020.05.27.20114413 (2020)  
431 doi:10.1101/2020.05.27.20114413.
- 432 12. Magadmi, R. M. & Kamel, F. O. Beliefs and Barriers Associated with COVID-19  
433 Vaccination Among the General Population in Saudi Arabia. (2020) doi:10.21203/rs.3.rs-  
434 48955/v1.
- 435 13. Abdelhafiz, A. S. *et al.* Knowledge, Perceptions, and Attitude of Egyptians Towards the  
436 Novel Coronavirus Disease (COVID-19). *J. Community Health* **45**, 881–890 (2020).
- 437 14. El-Elimat, T., AbuAlSamen, M. M., Almomani, B. A., Al-Sawalha, N. A. & Alali, F. Q.  
438 Acceptance and attitudes toward COVID-19 vaccines: A cross-sectional study from  
439 Jordan. *medRxiv* 2020.12.22.20248676 (2020) doi:10.1101/2020.12.22.20248676.
- 440 15. Muqattash, R., Niankara, I. & Traoret, R. I. Survey data for COVID-19 vaccine preference  
441 analysis in the United Arab Emirates. *Data Br.* **33**, 106446 (2020).
- 442 16. Cyranoski, D. Arab nations first to approve Chinese COVID vaccine - despite lack of  
443 public data. *Nature* vol. 588 548 (2020).
- 444 17. Wang, K. *et al.* Change of Willingness to Accept COVID-19 Vaccine and Reasons of  
445 Vaccine Hesitancy of Working People at Different Waves of Local Epidemic in Hong  
446 Kong, China: Repeated Cross-Sectional Surveys. *Vaccines* **9**, 62 (2021).
- 447 18. Confidence in coronavirus vaccines is rising globally, survey suggests | Imperial News |  
448 Imperial College London. [https://www.imperial.ac.uk/news/214074/confidence-  
449 coronavirus-vaccines-rising-globally-survey/](https://www.imperial.ac.uk/news/214074/confidence-coronavirus-vaccines-rising-globally-survey/).
- 450 19. Lewis, J. R. What Is Driving the Decline in People’s Willingness to Take the COVID-19  
451 Vaccine in the United States? *JAMA Heal. Forum* **1**, e201393 (2020).
- 452 20. Worldometer - real time world statistics. <https://www.worldometers.info/>.

- 453 21. Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19  
454 in real time. *The Lancet Infectious Diseases* vol. 20 533–534 (2020).
- 455 22. Eysenbach, G. Improving the quality of web surveys: The Checklist for Reporting Results  
456 of Internet E-Surveys (CHERRIES). *Journal of Medical Internet Research* vol. 6 (2004).
- 457 23. Guidotti, E. & Ardia, D. COVID-19 Data Hub. *J. Open Source Softw.* **5**, 2376 (2020).
- 458 24. Fisher, K. A. *et al.* Attitudes Toward a Potential SARS-CoV-2 Vaccine : A Survey of U.S.  
459 Adults. *Ann. Intern. Med.* **173**, 964–973 (2020).
- 460 25. Grech, V., Gauci, C. & Agius, S. Vaccine hesitancy among Maltese healthcare workers  
461 toward influenza and novel COVID-19 vaccination. *Early Hum. Dev.* (2020)  
462 doi:10.1016/j.earlhumdev.2020.105213.
- 463 26. Kreps, S. *et al.* Factors Associated With US Adults’ Likelihood of Accepting COVID-19  
464 Vaccination. *JAMA Netw. open* **3**, e2025594 (2020).
- 465 27. Ward, J. K. *et al.* The French public’s attitudes to a future COVID-19 vaccine: The  
466 politicization of a public health issue. *Soc. Sci. Med.* **265**, 113414 (2020).
- 467 28. Harapan, H. *et al.* Acceptance of a COVID-19 Vaccine in Southeast Asia: A Cross-  
468 Sectional Study in Indonesia. *Front. Public Heal.* **8**, 381 (2020).
- 469 29. Detoc, M. *et al.* Intention to participate in a COVID-19 vaccine clinical trial and to get  
470 vaccinated against COVID-19 in France during the pandemic. *Vaccine* **38**, 7002–7006  
471 (2020).
- 472 30. Kabamba Nzaji, M. *et al.* Acceptability of Vaccination Against COVID-19 Among  
473 Healthcare Workers in the Democratic Republic of the Congo *Pragmatic Obs. Res.*  
474 **Volume 11**, 103–109 (2020).
- 475 31. Knoll, M. D. & Wonodi, C. Oxford–AstraZeneca COVID-19 vaccine efficacy. *The Lancet*  
476 vol. 397 72–74 (2021).
- 477 32. Oxford Covid jab less effective against South African variant, study finds | World news |  
478 The Guardian. <https://www.theguardian.com/world/2021/feb/07/oxford-covid-jab-less-effective-against-south-african-variant-study-finds>.
- 479
- 480 33. MacDonald, N. E. *et al.* Vaccine hesitancy: Definition, scope and determinants. *Vaccine*  
481 **33**, 4161–4164 (2015).
- 482 34. Hussein, M. A. *et al.* national survey of potential acceptance of COVID-19 vaccines in  
483 healthcare workers in Egypt. *medRxiv* 2021.01.11.21249324 (2021)  
484 doi:10.1101/2021.01.11.21249324.  
485

# Figure 1


medRxiv preprint doi: <https://doi.org/10.1101/2021.03.09.21252764>; this version posted March 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



# Figure 2


medRxiv preprint doi: <https://doi.org/10.1101/2021.03.09.21252764>; this version posted March 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Yes All rights reserved. No reuse allowed without permission. No



# Figure 3


medRxiv preprint doi: <https://doi.org/10.1101/2021.03.09.21252764>; this version posted March 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



# Figure 4

medRxiv preprint doi: <https://doi.org/10.1101/2021.03.09.21252764>; this version posted March 10, 2021. The copyright holder for this preprint

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




# Figure 5

medRxiv preprint doi: <https://doi.org/10.1101/2021.03.09.21252764>; this version posted March 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

**A**

In your opinion, what is the best way to deal with the vaccine in your country?



**B**

In your opinion, to what extent do others in your country need the vaccine?

